Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
RNACthis companyCartesian Therapeutics, Inc.	$7.56	-1.44×	-1.48×	66.95×	-0.55×	-37.2%	100.0%	-3099.9%	-4658.6%	103.2%	-28.4%	-42.4%	-0.1×	0.82×	0×	8.65×	0.0%	2	-4.61	2	C+
AARDAardvark Therapeutics, Inc. Common Stock	$1.35	-4.97×	2.69×	0×	-4.17×	71.6%	0.0%	0.0%	0.0%	-54.0%	-58.6%	-18.9%	0×	0.81×	0×	10.61×	0.0%	1	-1.98	3	B-
AVTXAvalo Therapeutics, Inc.	$7.02	-3.11×	2.93×	4,125.96×	-2.96×	-86.5%	100.0%	-123601.7%	-132642.4%	-94.2%	-70.2%	-21.1%	0.03×	0.17×	0×	8.14×	0.0%	2	4.43	2	B-
FENCFennec Pharmaceuticals Inc.	$10.64	-21.39×	6.28×	4.93×	-24.6×	-158.5%	91.6%	-14.2%	-21.8%	-27.8%	-10.7%	-5.7%	0×	4.93×	-3.05×	6.34×	0.0%	5	4.08	1	D+
NAUTNautilus Biotechnolgy, Inc.	$2.36	-4.15×	1.57×	0×	-5.02×	-106.3%	0.0%	0.0%	0.0%	-37.6%	-35.7%	-21.1%	0.19×	-0.34×	0×	13.33×	0.0%	3	1.3	2	C
NTHINeonc Technologies Holdings, Inc.	$3.57	-2.56×	-9.07×	3,973.02×	-2.77×	-122.3%	100.0%	-145459.4%	-155404.4%	355.0%	519.7%	-13.1%	-0.36×	-0.1×	-23.23×	0.07×	0.0%	2	-66.25	2	C
Peer median	—	-4.15×	2.69×	4.93×	-4.17×	-106.3%	91.6%	-14.2%	-21.8%	-37.6%	-35.7%	-18.9%	0×	0.17×	0×	8.14×	0.0%	2	1.3	2	—